Vivos Therapeutics, Inc., a medical device and technology company, has announced a registered direct offering of common stock, expected to close on September 20, 2024. The offering, priced at-the-market under Nasdaq rules, involves the sale of 1,363,812 shares at $3.15 each, aiming to raise approximately $4.3 million. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The shares are being offered pursuant to an effective shelf registration statement previously filed with the SEC. Vivos has agreed to certain restrictions on the issuance and sale of its shares for 30 days post-closing and will not engage in any Variable Rate Transactions for one year, with some exceptions. The offering does not include any common stock purchase warrants.

Vivos Therapeutics, Inc., a medical device and technology company, has announced a registered direct offering of common stock, expected to close on September 20, 2024. The offering, priced at-the-market under Nasdaq rules, involves the sale of 1,363,812 shares at $3.15 each, aiming to raise approximately $4.3 million. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The shares are being offered pursuant to an effective shelf registration statement previously filed with the SEC. Vivos has agreed to certain restrictions on the issuance and sale of its shares for 30 days post-closing and will not engage in any Variable Rate Transactions for one year, with some exceptions. The offering does not include any common stock purchase warrants.